A Study of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine Tumors
Status:
Not yet recruiting
Trial end date:
2026-11-29
Target enrollment:
Participant gender:
Summary
pNENs still have a risk of recurrence after radical resection, and the overall recurrence and
metastasis rate is as high as 13.7%-36.2% in China. At present, there is no standard adjuvant
therapy for pNEN, and prospective studies are still lacking. This study was a randomized,
double-blind, placebo-controlled, multicenter clinical trial to explore the efficacy and
safety of surufatinib in the adjuvant treatment of pNET, in order to further improve the
prognosis of patients and to provide high-quality research evidence for adjuvant therapy.